Physician profile
Maeve Maher
NPI 1821451105
$3,612.60
in general payments reported to CMS, 2019-2025
23 companies · $47.99 in 2025
The $47.99 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $858 · 2021: $108 · 2022: $769 · 2023: $1,135 · 2024: $694 · 2025: $47.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,877.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,161.93 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $370.79 | 2019-2024 | Libtayo |
| Novartis Pharmaceuticals Corporation | $288.70 | 2021-2024 | |
| Lilly USA, LLC | $188.52 | 2022-2024 | Olumiant, Taltz |
| Mallinckrodt Enterprises LLC | $182.93 | 2019 | |
| Arcutis Biotherapeutics, INC. | $182.85 | 2023-2024 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $178.09 | 2023-2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $158.06 | 2022-2023 | Ilumya |
| Amgen INC. | $147.42 | 2022-2024 | Otezla |
| Pfizer INC. | $144.03 | 2022-2023 | |
| Stemline Therapeutics INC. | $119.54 | 2019 | |
| Galderma Laboratories, L.P. | $89.74 | 2023-2024 | Aklief |
| Ucb, INC. | $71.47 | 2023 | Cimzia |
| Dermavant Sciences, INC. | $55.79 | 2024 | Vtama |
| Almirall LLC | $43.52 | 2022-2024 | Klisyri |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $40.48 | 2022-2023 | |
| Incyte Corporation | $37.73 | 2023 | Opzelura |
| Janssen Biotech, INC. | $37.40 | 2022-2023 | Tremfya |
| Leo Pharma INC. | $33.08 | 2021-2024 | Adbry |
| Mayne Pharma Commercial LLC | $27.67 | 2022-2023 | |
| Krystal Biotech INC | $23.51 | 2023 | Vyjuvek |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.16 | 2022 | |
| Organon LLC | $7.19 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maeve Maher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.